# ZEAL-1L (NCT04475939)

> Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04475939
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: GlaxoSmithKline
- Conditions: Lung Cancer, Non-Small Cell
- Interventions: Niraparib; Pembrolizumab; Placebo
- Enrollment: 666
- Primary outcome: Progression-free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) - Complete and Partial Response (CR/PR) Population

## Commentary we found

- X threads: 6

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=zeal-1l-nct04475939